JP2007510671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510671A5 JP2007510671A5 JP2006538531A JP2006538531A JP2007510671A5 JP 2007510671 A5 JP2007510671 A5 JP 2007510671A5 JP 2006538531 A JP2006538531 A JP 2006538531A JP 2006538531 A JP2006538531 A JP 2006538531A JP 2007510671 A5 JP2007510671 A5 JP 2007510671A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycle
- aryl
- pharmaceutical composition
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCC(C1=C2*)NN=C1c1ccccc1C2=O Chemical compound CCCC(C1=C2*)NN=C1c1ccccc1C2=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51860103P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/037084 WO2005046594A2 (en) | 2003-11-06 | 2004-11-04 | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510671A JP2007510671A (ja) | 2007-04-26 |
| JP2007510671A5 true JP2007510671A5 (https=) | 2007-09-20 |
Family
ID=34590281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538531A Pending JP2007510671A (ja) | 2003-11-06 | 2004-11-04 | アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070270448A1 (https=) |
| EP (1) | EP1684690A4 (https=) |
| JP (1) | JP2007510671A (https=) |
| KR (1) | KR20060124610A (https=) |
| CN (1) | CN1901903A (https=) |
| AU (1) | AU2004288715A1 (https=) |
| BR (1) | BRPI0416266A (https=) |
| CA (1) | CA2544591A1 (https=) |
| IL (1) | IL175428A0 (https=) |
| WO (1) | WO2005046594A2 (https=) |
| ZA (1) | ZA200603719B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| JP2011529504A (ja) | 2008-07-28 | 2011-12-08 | ギリアード サイエンシーズ， インコーポレイテッド | シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物 |
| US20100183633A1 (en) * | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| WO2010144378A2 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| WO2018035454A1 (en) * | 2016-08-19 | 2018-02-22 | Memorial Sloan-Kettering Cancer Center | Methods of differentiating stem cells into endoderm |
| CN113698408B (zh) * | 2020-05-22 | 2025-07-25 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3095415A (en) * | 1958-05-30 | 1963-06-25 | Ciba Ltd | Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group |
| CH428043A (fr) * | 1965-08-16 | 1967-01-15 | Sandoz Ag | Procédé de fabrication de colorants de dispersion isothiazolantroniques |
| US3541110A (en) * | 1967-01-20 | 1970-11-17 | American Home Prod | Indazole-5-sulfonamides |
| JPS63184364A (ja) * | 1987-01-27 | 1988-07-29 | Toshiba Corp | 半導体装置の製造方法 |
| DK0851753T3 (da) * | 1995-09-19 | 2004-03-15 | Fujisawa Pharmaceutical Co | Aerosolpræparater |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0973767A1 (en) * | 1997-03-31 | 2000-01-26 | Dupont Pharmaceuticals Company | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| DE69821011T3 (de) * | 1997-10-02 | 2009-01-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| HK1053107A1 (zh) * | 1999-08-19 | 2003-10-10 | Signal Pharmaceuticals, Inc. | 作为jnk抗化剂的pyrazoloanthrone及其衍生物和它们的成份 |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| US6987184B2 (en) * | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| AU2003217961B2 (en) * | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| AU2004293443A1 (en) * | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc. | Indazole Compounds and methods of use thereof as protein kinase inhibitors |
-
2004
- 2004-11-04 AU AU2004288715A patent/AU2004288715A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/037084 patent/WO2005046594A2/en not_active Ceased
- 2004-11-04 JP JP2006538531A patent/JP2007510671A/ja active Pending
- 2004-11-04 EP EP04800843A patent/EP1684690A4/en not_active Withdrawn
- 2004-11-04 CN CNA2004800400028A patent/CN1901903A/zh active Pending
- 2004-11-04 CA CA002544591A patent/CA2544591A1/en not_active Abandoned
- 2004-11-04 US US10/578,809 patent/US20070270448A1/en not_active Abandoned
- 2004-11-04 BR BRPI0416266-8A patent/BRPI0416266A/pt not_active IP Right Cessation
- 2004-11-04 KR KR1020067011021A patent/KR20060124610A/ko not_active Withdrawn
- 2004-11-04 ZA ZA200603719A patent/ZA200603719B/en unknown
-
2006
- 2006-05-04 IL IL175428A patent/IL175428A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533748A5 (https=) | ||
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2020516621A5 (https=) | ||
| WO2009103076A1 (en) | Methods and compositions for enhancing the efficacy of rtk inhibitors | |
| DE10178132T1 (de) | Antivirales Mittel | |
| RU2357734C2 (ru) | КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| JP2016502544A5 (https=) | ||
| JP2001517250A (ja) | ナフタレンスルホン酸誘導体を含有する相乗作用抗腫瘍組成物 | |
| JP2007510671A5 (https=) | ||
| JP2019507111A5 (https=) | ||
| WO2013096684A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2021522197A5 (https=) | ||
| JPH0656698A (ja) | 潰瘍胃腸症状の予防もしくは治療用組成物 | |
| JP2019524852A5 (https=) | ||
| JP2007500201A (ja) | エクチナサイジン−７４３と白金抗腫瘍化合物との併用 | |
| CZ302451B6 (cs) | Protirakovinová farmaceutická kombinace | |
| JPWO2020163823A5 (https=) | ||
| AU2006236812A1 (en) | Combinations, methods and compositions for treating cancer | |
| JP2007530582A5 (https=) | ||
| JP2005535594A5 (https=) | ||
| JP2019513812A5 (https=) | ||
| HUP0401153A2 (hu) | Epothilone-származékokat tartalmazó kombinációk és azok gyógyszerészeti felhasználása | |
| JP2007500240A5 (https=) |